The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

por Kawakami, Hisato, Okamoto, Isamu, Yonesaka, Kimio, Okamoto, Kunio, Shibata, Kiyoko, Shinkai, Yume, Sakamoto, Haruka, Kitano, Michiko, Tamura, Takao, Nishio, Kazuto, Nakagawa, Kazuhiko
Publicado 2014

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors

por Fujisaka, Yasuhito, Kurata, Takayasu, Tanaka, Kaoru, Kudo, Toshihiro, Okamoto, Kunio, Tsurutani, Junji, Kaneda, Hiroyasu, Okamoto, Isamu, Namiki, Masayuki, Kitamura, Chifumi, Nakagawa, Kazuhiko
Publicado 2014

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer

por Tsurutani, Junji, Kuroi, Katsumasa, Iwasa, Tsutomu, Miyazaki, Masaki, Nishina, Shinichi, Makimura, Chihiro, Tanizaki, Junko, Okamoto, Kunio, Yamashita, Toshinari, Aruga, Tomoyuki, Shigekawa, Takashi, Komoike, Yoshifumi, Saeki, Toshiaki, Nakagawa, Kazuhiko
Publicado 2015

Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection

por Kidera, Yasuhiro, Kawakami, Hisato, Sakiyama, Tsutomu, Okamoto, Kunio, Tanaka, Kaoru, Takeda, Masayuki, Kaneda, Hiroyasu, Nishina, Shin-ichi, Tsurutani, Junji, Fujiwara, Kimiko, Nomura, Morihiro, Yamazoe, Yuzuru, Chiba, Yasutaka, Nishida, Shozo, Tamura, Takao, Nakagawa, Kazuhiko
Publicado 2014

Clinicopathological examination of ESD as salvage therapy for esophageal cancer after definitive chemo-radiation therapy

por Kagawa, Tomo, Ishikawa, Shigenao, Inaba, Tomoki, Colvin, Mariko, Toyosawa, Junki, Aoyama, Yuki, Ishida, Masaya, Kuraoka, Sakiko, Okamoto, Kunio, Sakakihara, Ichiro, Izumikawa, Koichi, Yamamoto, Kumiko, Takahashi, Sakuma, Tanaka, Shigetomi, Matsuura, Mihoko, Hasui, Toshimi, Wato, Masaki, Ando, Midori, Nakamura, Satoko, Mizobuchi, Koichi
Publicado 2018